The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

[1]  E. Hagström,et al.  Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. , 2016, European heart journal.

[2]  Claes Held,et al.  The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation , 2016, European heart journal.

[3]  Ulrika Andersson,et al.  Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation , 2016, Heart.

[4]  M. Ezekowitz,et al.  Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. , 2015, American heart journal.

[5]  Emily C. O'Brien,et al.  The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation , 2015, European heart journal.

[6]  Jun Zhu,et al.  Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. , 2015, European heart journal.

[7]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[8]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[9]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[10]  R. de Caterina,et al.  Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2014, Circulation.

[11]  E. Hylek,et al.  D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial , 2014, Journal of thrombosis and haemostasis : JTH.

[12]  Yvonne Vergouwe,et al.  Towards better clinical prediction models: seven steps for development and an ABCD for validation. , 2014, European heart journal.

[13]  R. de Caterina,et al.  Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. , 2014, Journal of the American College of Cardiology.

[14]  S. Yusuf,et al.  Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy , 2014, Heart.

[15]  D. Atar,et al.  High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. , 2014, Journal of the American College of Cardiology.

[16]  S. Yusuf,et al.  Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.

[17]  D. Atar,et al.  High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2013, Circulation.

[18]  L. Lind,et al.  GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.

[19]  G. Breithardt,et al.  Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[20]  S. Hohnloser,et al.  N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). , 2013, Journal of the American College of Cardiology.

[21]  C. Granger,et al.  Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.

[22]  P. Royston,et al.  External validation of a Cox prognostic model: principles and methods , 2013, BMC Medical Research Methodology.

[23]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[24]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[25]  Robby Nieuwlaat,et al.  Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey , 2012 .

[26]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[27]  Ottavio Alfieri,et al.  Corrigendum to: ‘Guidelines for the management of atrial fibrillation’ [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420] , 2011 .

[28]  D. Singer,et al.  Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation , 2011, Circulation. Cardiovascular quality and outcomes.

[29]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[30]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[31]  B. Gersh,et al.  Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. , 2010, American heart journal.

[32]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[33]  S. Yusuf,et al.  Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. , 2009, American heart journal.

[34]  Elena B. Elkin,et al.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers , 2008, BMC Medical Informatics Decis. Mak..

[35]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[36]  A.G. Messenger,et al.  Guidelines Guidelines for the management of alopecia areata , 2003 .

[37]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[38]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.